Combination therapy of vaccinia virus infection with human anti-H3 and anti-B5 monoclonal antibodies in a small animal model
Antiviral Therapy2010Vol. 15(4), pp. 661–675
Citations Over TimeTop 18% of 2010 papers
Megan McCausland, Mohammed Rafii‐El‐Idrissi Benhnia, Lindsay Crickard, John Laudenslager, Steven W. Granger, Tomoyuki Tahara, Ralph T. Kubo, Lilia K. Koriazova, Shinichiro Kato, Shane Crotty
Abstract
The preclinical studies validate that this combination of mAbs against H3 and B5 is a promising approach as a poxvirus infection treatment for use in humans.
Related Papers
- → Treatment of Vaccinia and Cowpox Virus Infections in Mice with CMX001 and ST-246(2010)27 cited
- → Orf virus and vaccinia virus do not cross-protect sheep(1988)17 cited
- → Inhibitory Effect of Heated Vaccinia Virus on Growth of Vaccinia Virus in Earle's L Cells.(1961)5 cited
- Interaction of vaccinia virus with adenocarcinoma 755.(1963)
- → Titration of Rabbit Kidney Vacuolating Virus by Its Interference With Vaccinia Virus in Tissue Culture(1968)1 cited